Table 8.
Series of grade I meningiomas and respective percentages of PR expression.
|
Authors, year, country |
No. of cases of grade I meningiomas |
Percentage of PR immunoreactivity ± SD |
Relation between PR+ and PR- and recurrence: (p-value) |
|---|---|---|---|
| Current paper | 96 | 62.0 | p = 0.845 |
| Fewings et al., 2000, England (79) | 60 | 48.0 | 46 with long FU more recurrent tumors in PR- (p = 0.013) |
| Das et al., 2002, Thailand (76) | 90 | 67.0 | |
| Konstantinidou et al., 2003, Greece (82) | 38 | 75.5 | More recurrent tumors in PR- |
| Wolfsberger et al., 2004, Austria/Germany (81) | 51 | 22.9 ± 3.7 | |
| Roser et al., 2005, Germany (77) | 385 | <70 years: 56.1 ≥70 years: 58.4 p > 0.05 |
|
| Lusis et al., 2005, USA (58) | 5 | 100.0 | |
| Korhonen et al., 2006, Finland (11) | 407 primary tumors | 88.8 | p = 0.43 |
| Omulecka et al., 2006, Poland (62) | 46 | Meningothelial 100.0 Transitional 95.2 Fibrous 42.2 |
|
| Maiuri et al., 2007, Italy (63) | 57 | Recurrent 18.5 Primary 30.0 |
more recurrent tumors in PR- (p = 0.0001) |
| Taghipour et al., 2007, Iran (78) | 51 | 68.6 | |
| Takei et al., 2008, USA (9) | 46 | 92.1 | |
| Kandemir et al., 2010, Turkey (71) | 53 | 50.9 | |
| Kärjä et al., 2010, Finland/Sweden (13) | 59 | Recurrent 47.6 ± 9.2 Primary 48.9 ± 6.8 |
p = 0.331 |
| Shayanfar et al., 2010, Iran (80) | 63 | 96.8 | |
| Abdelzaher et al., 2011, Egypt (51) | 60 | 70.0 | p > 0.05 |
| Iplikcioglu et al., 2014, Turkey (14) | 26 | 73.0 | p = 0.69 |
| Mukhopadhyay et al., 2017, India (73) | 82 | 96.34 |
PR, progesterone receptor; PR+, positive immunoreactivity for PR; PR-, negative immunoreactivity for PR; SD, standard deviation.